Altitude pill may also fight inflammation, early study hints

NCT ID NCT07517068

Ongoing Knowledge-focused Sponsor: University of California, Riverside Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether acetazolamide, a drug already used for altitude sickness, can reduce inflammation and immune system activation caused by high altitude. Nineteen healthy adults will take either the drug or a placebo before and during a stay at 3800 meters. Researchers will measure changes in immune cells and inflammatory markers in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Acetazolamide
What this could lead to: If successful, this could help explain how acetazolamide prevents altitude sickness and may point to new ways to control inflammation.
What could go wrong: This is a very small, early-phase study (19 people) looking at blood markers, not symptoms. Results may not apply to the general public or lead to a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MOUNTAIN SICKNESS (AMS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute mountain sickness altitude sickness Hypoxia Inflammation inflammatory disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MOUNTAIN SICKNESS (AMS) HYPOXEMIA IMMUNE RESPONSE INFLAMMATION

Contacts and locations

Locations

University of California, Riverside

Riverside, California, 92521, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.